Clinical Trials Directory

Trials / Unknown

UnknownNCT01670903

The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
150 (estimated)
Sponsor
Sheba Medical Center · Other Government
Sex
All
Age
50 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Abdominal aortic aneurysm (AAA) is a common disease that develops from degeneration of the aortic wall. The natural history of AAA is gradual expansion and if left untreated may result in rupture and death. The mechanism of the development of this disease is unknown however it appears to be multifactorial and possibly related to degradation processes within the arterial wall. There is growing evidence that Angiotensin receptor blockers ( ARBS) may have an inhibitory effect on remodelling processes within the arterial wall, thus inhibiting degeneration of the vessel wall. Study hypothesis: ARBS are associated with smaller diameters of aortas among hypertensive patients, and are associated with a lower rate of aortic expansion compared to other antihypertensive drugs.

Conditions

Timeline

Start date
2011-05-01
First posted
2012-08-22
Last updated
2012-08-22

Locations

2 sites across 1 country: Israel

Source: ClinicalTrials.gov record NCT01670903. Inclusion in this directory is not an endorsement.

The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertens (NCT01670903) · Clinical Trials Directory